다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (CRVS) 뉴스

CRVS

Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CRVS

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/08	06:19	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/08	06:16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/08	06:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05:11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05:01	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/03	05:02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/02	21:30	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/04/10	05:01	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/20	05:02	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/19	20:27	IH Market News	US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/14	05:02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/02	07:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/12	22:30	GlobeNewswire Inc.	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/09	06:27	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/09	06:05	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/07	06:05	GlobeNewswire Inc.	Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/01/24	07:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/01/24	07:00	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/10	02:00	GlobeNewswire Inc.	Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/09	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/09	06:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06:02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06:01	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/02	22:15	GlobeNewswire Inc.	Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/02	08:31	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/01	05:02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/09/07	05:05	GlobeNewswire Inc.	Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/08/09	05:02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:CRVS

1 2 3 4 5 6 7 8 9 10 다음 >>

Societe Generale Effekten

Nippon Sharyo Seizo (PK)

Slovenske Energeticke St...

Vontobel Financial Produ...

True Inverse 2x Vietnam ...

Caisse Amort Dette Socia...

Stanley Black and Decker

Vontobel Financial Produ...

Kolibri Global Energy (QB)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관